Medindia

X

InterMune Reports Top-Line Results From Phase 2b Study of Danoprevir (RG7227/ITMN-191) in Patients with Chronic Hepatitis C

Thursday, April 15, 2010 Research News J E 4
Advertisement

Number (%) of Patients(1) with Virologic Response (<LOD)(2)

Background therapy Pegasys/Copegus

+300 mg

q8h

(n=67)

+600 mg

q12h

(n=65)

+900 mg

q12h

(n=50)

+Placebo

(n=30)

Week 4 (RVR(3))

49 (73%)

56 (86%)

43 (86%)

2 (7%)

Week 12

(cEVR(4))

59 (88%)

58 (89%)

46 (92%)

13 (43%)

(1)  Missing data counted as non-response

(2)  Virologic Response = HCV RNA below the limit of detection (<LOD) as measured by Roche COBAS TaqMan HCV Test (<15 IU/mL)

(3)  RVR – Rapid Virologic Response

(4)  cEVR – complete Early Virologic Response

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
MAP Pharmaceuticals Announces Potential of LEVADEX...
S
Terumo Heart, Inc. Submits IDE to FDA for U.S. Des...